“…1 ). We selected several reported anti-HCV agents, such as 2′- C -methylcytidine (compound 2) ( 9 ), sofosbuvir (compound 4), a novel prodrug of sofosbuvir (compound 3) ( 10 ), and two 2′-dihalogeno nucleoside prodrugs (compounds 6 and 7) ( 11 , 12 ). We also selected ALS-8112 (compound 5) ( 13 ), the active form of lumicitabine, a drug developed until recently for the treatment of respiratory syncytial virus (RSV) ( 14 ).…”